Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92671 | 0.82 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1CHRM5CHKA | |
| SCHEMBL85222 | 0.80 | ALDH1A1 (0.36) | LMNASMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL85213 | 0.73 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1HPGDNPSR1NAMPT | |
| SCHEMBL13812295 | 0.72 | ALDH1A1 (0.39) | LMNASMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL5656924 | 0.70 | CHRM5 (0.50) | LMNASMN1; SMN2HPGDCHRM5CHKA | |
| SCHEMBL9911480 | 0.69 | CA1 (0.44) | LMNASMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL15867019 | 0.68 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1CHRM5CHKA | |
| SCHEMBL5856313 | 0.67 | MLYCD (0.51) | LMNASMN1; SMN2CHRM5CHKAPTGS2 | |
| SCHEMBL13764331 | 0.66 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL1911525 | 0.65 | MDM2 (0.59) | LMNASMN1; SMN2ALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8088778-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7807828-B2 | Olanzapine analogs and methods of use thereof | HYPNION, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807828-B2 | Olanzapine analogs and methods of use thereof | HYPNION, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-7563785-B2 | Quetiapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | GABRB3, GRIN2C, GABRB2 | LMNA 3074/4885SMN1; SMN2 3529/4885ALDH1A1 1166/4885 |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | LMNA 1104/4885SMN1; SMN2 2573/4885ALDH1A1 1099/4885 |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | LMNA 1382/4885SMN1; SMN2 2872/4885ALDH1A1 1540/4885 |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | HCRTR2, HCRTR1, HTR3B | LMNA 195/4885SMN1; SMN2 2083/4885ALDH1A1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.